Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.59 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 7.05 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -36.9 | |||||
| 3-Year FCF Growth Rate | -33.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.59 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.05 | |||||
| 9-Day RSI | 34.04 | |||||
| 14-Day RSI | 33.2 | |||||
| 6-1 Month Momentum % | -50.59 | |||||
| 12-1 Month Momentum % | -68.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.08 | |||||
| Quick Ratio | 1.08 | |||||
| Cash Ratio | 1.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -19.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -220.38 | |||||
| ROA % | -83.14 | |||||
| ROIC % | -247.16 | |||||
| 3-Year ROIIC % | -128.47 | |||||
| ROC (Joel Greenblatt) % | -8895.28 | |||||
| ROCE % | -169.24 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.09 | |||||
| EV-to-EBITDA | -0.09 | |||||
| EV-to-Forward-Revenue | 0.56 | |||||
| EV-to-FCF | -0.1 | |||||
| Price-to-Net-Cash | 9.2 | |||||
| Earnings Yield (Greenblatt) % | -1111.11 | |||||
| FCF Yield % | -396.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.074 | ||
| Beta | 0.57 | ||
| Volatility % | 173.82 | ||
| 14-Day RSI | 33.2 | ||
| 14-Day ATR (€) | 0.016115 | ||
| 20-Day SMA (€) | 0.21275 | ||
| 12-1 Month Momentum % | -68.76 | ||
| 52-Week Range (€) | 0.167 - 1.24 | ||
| Shares Outstanding (Mil) | 39.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viracta Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(FRA:RYI)'s stock price today?
The current price of FRA:RYI is €0.18. The 52 week high of FRA:RYI is €1.24 and 52 week low is €0.17.
When is next earnings date of Viracta Therapeutics Inc(FRA:RYI)?
The next earnings date of Viracta Therapeutics Inc(FRA:RYI) is 2024-11-08 Est..
Does Viracta Therapeutics Inc(FRA:RYI) pay dividends? If so, how much?
Viracta Therapeutics Inc(FRA:RYI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers